|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2002-10-2
|
|
pubmed:abstractText |
The 5-HT3 receptor (5-HT3R) antagonist Alosetron (Alos) reduces the symptoms of female patients with diarrhea-predominant irritable bowel syndrome (IBS); yet, the mechanism(s) underlying this effect remains incompletely understood. We determined the effect of Alos on regional cerebral blood flow (rCBF) in the absence and presence of rectal or sigmoid stimulation to evaluate 2 hypothesized mechanisms of therapeutic action: peripheral antinociception and inhibition of emotional motor system (EMS) regions in the brain.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0016-5085
|
|
pubmed:author |
pubmed-author:BermanSteven MSM,
pubmed-author:ChangLinL,
pubmed-author:DerbyshireStuart WSW,
pubmed-author:FitzgeraldLeahL,
pubmed-author:HammLynnL,
pubmed-author:MandelkernMarkM,
pubmed-author:MayerEmeran AEA,
pubmed-author:NaliboffBruce DBD,
pubmed-author:StainsJeanJ,
pubmed-author:SuyenobuBrandallB,
pubmed-author:VogtBrentB
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
123
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
969-77
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12360456-Adult,
pubmed-meshheading:12360456-Balloon Dilation,
pubmed-meshheading:12360456-Brain,
pubmed-meshheading:12360456-Brain Chemistry,
pubmed-meshheading:12360456-Carbolines,
pubmed-meshheading:12360456-Colon,
pubmed-meshheading:12360456-Colonic Diseases, Functional,
pubmed-meshheading:12360456-Female,
pubmed-meshheading:12360456-Gastrointestinal Agents,
pubmed-meshheading:12360456-Humans,
pubmed-meshheading:12360456-Male,
pubmed-meshheading:12360456-Middle Aged,
pubmed-meshheading:12360456-Perception,
pubmed-meshheading:12360456-Receptors, Serotonin,
pubmed-meshheading:12360456-Receptors, Serotonin, 5-HT3,
pubmed-meshheading:12360456-Tomography, Emission-Computed
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron.
|
|
pubmed:affiliation |
CURE/Neuroenteric Disease Program, Department of Medicine, University of California School of Medicine, Los Angeles, California 90073, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
